Cellectis SA Company Profile (NASDAQ:CLLS)

About Cellectis SA

Cellectis SA logoCellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. The Company also offers rational inverse genetics and targeting recombination tools. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CLLS
  • CUSIP:
Key Metrics:
  • Previous Close: $26.97
  • 50 Day Moving Average: $26.54
  • 200 Day Moving Average: $27.19
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -11.83
  • P/E Growth: 0.00
  • Market Cap: $950.10M
  • Outstanding Shares: 35,228,000
  • Beta: 2.23
Additional Links:
Companies Related to Cellectis SA:

Analyst Ratings

Consensus Ratings for Cellectis SA (NASDAQ:CLLS) (?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $47.25 (75.19% upside)

Analysts' Ratings History for Cellectis SA (NASDAQ:CLLS)
Show:
DateFirmActionRatingPrice TargetDetails
8/5/2016Jefferies GroupReiterated RatingBuyView Rating Details
7/27/2016Oppenheimer Holdings Inc.Reiterated RatingOutperform$65.00View Rating Details
5/8/2016Piper Jaffray Cos.Reiterated RatingBuyView Rating Details
4/5/2016Ladenburg ThalmannInitiated CoverageBuy$45.00View Rating Details
3/1/2016SunTrust Banks Inc.Initiated CoverageBuy$35.00View Rating Details
7/20/2015Bank of America Corp.Initiated CoverageBuy$50.00View Rating Details
(Data available from 8/25/2014 forward)

Earnings

Earnings History for Cellectis SA (NASDAQ:CLLS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/12/2016Q116($0.35)($0.53)ViewN/AView Earnings Details
3/16/2016Q415($0.30)$0.65ViewN/AView Earnings Details
11/19/2015Q215($0.43)($0.10)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cellectis SA (NASDAQ:CLLS)
Current Year EPS Consensus Estimate: $-1.73 EPS
Next Year EPS Consensus Estimate: $-2.28 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.56)($0.43)($0.50)
Q2 20163($0.65)($0.44)($0.55)
Q3 20163($0.65)($0.45)($0.56)
Q4 20163($0.65)($0.46)($0.57)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Cellectis SA (NASDAQ:CLLS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Cellectis SA (NASDAQ:CLLS)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Cellectis SA (NASDAQ:CLLS)
DateHeadline
News IconStock Noted Gapping Up Pre-Bell: Cellectis S.A. (NASDAQ:CLLS) - Post News (NASDAQ:CLLS)
www.kentuckypostnews.com - August 23 at 8:26 AM
seekingalpha.com logoRegeneron's Q2: Opportunities And Challenges - Seeking Alpha (NASDAQ:CLLS)
seekingalpha.com - August 5 at 12:22 PM
benzinga.com logoImportance Of Phase 1 Trials - Benzinga (NASDAQ:CLLS)
www.benzinga.com - July 23 at 8:33 AM
finance.yahoo.com logoImportance Of Phase 1 Trials (NASDAQ:CLLS)
finance.yahoo.com - July 22 at 2:18 PM
capitalcube.com logoETF’s with exposure to Cellectis SA : July 21, 2016 (NASDAQ:CLLS)
www.capitalcube.com - July 21 at 1:53 PM
fiscalstandard.com logoBroker Outlook For Cellectis S.A. (CLLS) - Fiscal Standard (NASDAQ:CLLS)
www.fiscalstandard.com - July 20 at 11:56 AM
fiscalstandard.com logoNext Weeks Broker Price Targets For Cellectis S.A. (CLLS) - Fiscal Standard (NASDAQ:CLLS)
www.fiscalstandard.com - July 17 at 8:52 AM
ftsenews.co.uk logoNew Broker Ratings For Cellectis S.A. (CLLS) - FTSE News (NASDAQ:CLLS)
www.ftsenews.co.uk - July 15 at 3:20 PM
benzinga.com logoJuno Therapeutics Soars 25% After ROCKET Phase 2 Rocket Trial Resumption - Benzinga (NASDAQ:CLLS)
www.benzinga.com - July 13 at 4:22 PM
News IconCellectis SA (ADR) Can't Be More Safe. Trades Significantly Higher - Consumer Eagle (NASDAQ:CLLS)
www.consumereagle.com - July 13 at 4:22 PM
fiscalstandard.com logoCellectis S.A. (CLLS) Current Analyst Ratings - Fiscal Standard (NASDAQ:CLLS)
www.fiscalstandard.com - July 13 at 4:22 PM
investors.com logoJuno Therapeutics Stock Spikes After Cancer Trial Resumes (NASDAQ:CLLS)
www.investors.com - July 13 at 10:34 AM
kcregister.com logoMoving Stocks: Cellectis S.A. (NASDAQ:CLLS), 3M Company (NYSE:MMM), Telefonaktiebolaget LM Ericsson ... - KC Register (NASDAQ:CLLS)
www.kcregister.com - July 12 at 8:29 AM
kcregister.com logoCellectis S.A. (NASDAQ:CLLS) Rose 2.48%: Petroleo Brasileiro Petrobras SA (ADR) (NYSE:PBR), Liberty Tax, Inc ... - KC Register (NASDAQ:CLLS)
www.kcregister.com - July 6 at 4:22 PM
fiscalstandard.com logoRecently Issued Stock Ratings For Cellectis S.A. (CLLS) - Fiscal Standard (NASDAQ:CLLS)
www.fiscalstandard.com - June 30 at 4:29 PM
publicnow.com logoMIT Technology Review Names Cellectis on Annual List of 50 Smartest Companies for Second Consecutive Year (NASDAQ:CLLS)
www.publicnow.com - June 27 at 5:41 PM
publicnow.com logoCellectis Named 2016 Technology Pioneer by the World Economic Forum (NASDAQ:CLLS)
www.publicnow.com - June 27 at 5:41 PM
News IconCellectis SA Ads (NASDAQ:CLLS) Shorted Shares Decreased By 12.67% - Engelwood Daily (NASDAQ:CLLS)
www.engelwooddaily.com - June 27 at 4:12 PM
fiscalstandard.com logoCellectis S.A. (CLLS) Broker Price Targets For The Coming Week - Fiscal Standard (NASDAQ:CLLS)
www.fiscalstandard.com - June 27 at 4:12 PM
ftsenews.co.uk logoCellectis S.A. (CLLS) Updated Price Targets - FTSE News (NASDAQ:CLLS)
www.ftsenews.co.uk - June 23 at 11:35 PM
publicnow.com logoCellectis Announces First Patient Treated in Phase 1 Trial of UCART19 in Pediatric Acute B Lymphoblastic Leukemia (B-ALL) (NASDAQ:CLLS)
www.publicnow.com - June 20 at 5:59 PM
capitalcube.com logoETF’s with exposure to Cellectis SA : June 20, 2016 (NASDAQ:CLLS)
www.capitalcube.com - June 20 at 2:13 PM
kcregister.com logoEarnings to Watch: Digital Turbine, Inc. (NASDAQ:APPS), Cellectis S.A. (NASDAQ:CLLS), MV Oil Trust (NYSE:MVO ... - KC Register (NASDAQ:CLLS)
www.kcregister.com - June 13 at 3:42 PM
News IconAfter Last Week What Do Analysts Think Of Cellectis S.A. (CLLS) - Share Trading News (NASDAQ:CLLS)
www.sharetrading.news - June 5 at 12:03 PM
News IconCellectis SA's (CLLS) “Buy” Rating Reaffirmed at Oppenheimer - Let Me Know About This (NASDAQ:CLLS)
www.lmkat.com - June 4 at 12:49 PM
News IconBuy, Sell Or Hold Rating For Cellectis S.A. (CLLS)? - Share Trading News (NASDAQ:CLLS)
www.sharetrading.news - June 3 at 4:25 PM
capitalcube.com logoETF’s with exposure to Cellectis SA : June 3, 2016 (NASDAQ:CLLS)
www.capitalcube.com - June 3 at 3:13 PM
News IconCellectis S.A. (CLLS) Do Brokers Advise Buy, Sell Or Hold? - Share Trading News (NASDAQ:CLLS)
www.sharetrading.news - June 1 at 4:23 PM
capitalcube.com logoCellectis SA :CLLS-US: Earnings Analysis: Q1, 2016 By the Numbers : June 1, 2016 (NASDAQ:CLLS)
www.capitalcube.com - June 1 at 12:49 PM
News IconCellectis SA (CLLS) Earns Buy Rating from Piper Jaffray - Let Me Know About This (NASDAQ:CLLS)
www.lmkat.com - May 30 at 11:41 PM
News IconNext Weeks Broker Price Targets For Cellectis S.A. (CLLS) - Share Trading News (NASDAQ:CLLS)
www.sharetrading.news - May 30 at 1:34 PM
finance.yahoo.com logoCalyxt Appoints Federico A. Tripodi to New Role of CEO (NASDAQ:CLLS)
finance.yahoo.com - May 23 at 5:00 PM
publicnow.com logoCellectis S.A. Reports Results from Shareholders’ General Meeting Held on May 17, 2016 (NASDAQ:CLLS)
www.publicnow.com - May 19 at 6:02 PM
publicnow.com logoCellectis Reports First Quarter 2016 Financial Results (NASDAQ:CLLS)
www.publicnow.com - May 11 at 7:07 PM
publicnow.com logoFirst Quarter 2016 Financial Results (NASDAQ:CLLS)
www.publicnow.com - May 11 at 7:07 PM
finance.yahoo.com logoCellectis' gene editing breakthrough: CEO (NASDAQ:CLLS)
finance.yahoo.com - May 9 at 6:41 AM
publicnow.com logoAACR Posters 2016 (NASDAQ:CLLS)
www.publicnow.com - May 6 at 8:14 PM
publicnow.com logoASGCT Posters 2016 (NASDAQ:CLLS)
www.publicnow.com - May 6 at 7:14 PM
publicnow.com logoCellectis to Present Data on its Allogeneic CAR T-Cell Programs at the 19th American Society of Gene & Cell Therapy Annual Meeting (NASDAQ:CLLS)
www.publicnow.com - May 2 at 5:20 PM
publicnow.com logoConsolidated financial statements - Year ended December 31, 2015 (NASDAQ:CLLS)
www.publicnow.com - April 28 at 12:24 PM
finance.yahoo.com logoCELLECTIS S.A. Financials (NASDAQ:CLLS)
finance.yahoo.com - March 25 at 1:04 PM
publicnow.com logoCellectis Announces RetroNectin® Supply and License Agreement with Takara Bio Inc. (NASDAQ:CLLS)
www.publicnow.com - March 21 at 5:54 PM
News IconCellectis SA (ADR) (CLLS) is Initiated by Sun Trust Rbsn Humphrey to Buy - Los Angeles Mirror (NASDAQ:CLLS)
www.losangelesmirror.net - March 2 at 2:48 PM
finance.yahoo.com logoCoverage initiated on Cellectis by Sun Trust Rbsn Humphrey (NASDAQ:CLLS)
finance.yahoo.com - March 2 at 7:41 AM
finance.yahoo.com logoCellectis Subsidiary Calyxt, Acquires Land for New Headquarters Facility (NASDAQ:CLLS)
finance.yahoo.com - March 1 at 9:00 PM
News IconCellectis SA Ads (NASDAQ:CLLS) Sellers Increased By 11.35% Their Shorts - Business Standard Tribune (NASDAQ:CLLS)
www.standardtrib.com - February 28 at 2:19 PM
clintongazette.com logoCellectis SA Ads (NASDAQ:CLLS) Shorts Decreased by 2.07% After Short Covering - Clinton Financial (NASDAQ:CLLS)
www.clintongazette.com - February 24 at 2:47 PM
News IconUpdated Price Targets On Cellectis S.A. (CLLS) - Risers & Fallers (NASDAQ:CLLS)
www.risersandfallers.com - February 22 at 2:26 PM
News IconCellectis SA (ADR) (NASDAQ:CLLS) announced that it entered into a new agreement for the cGMP manufacturing of ... - Inside Trade (NASDAQ:CLLS)
insidetrade.co - February 18 at 2:22 PM
News IconCellectis SA (ADR) (CLLS) Stock Surges 18% – Why is this stock up so much? - Independent Reporter (NASDAQ:CLLS)
ir.net - February 16 at 2:35 PM

Social

Cellectis SA (NASDAQ:CLLS) Chart for Thursday, August, 25, 2016


Last Updated on 8/25/2016 by MarketBeat.com Staff